Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Yaupon Therapeutics Completes Patient Enrollment For Pivotal Phase 2 Study Of Clearazide For Treatment Of Cutaneous T-cell Lymphoma
Yaupon Therapeutics, a privately held specialty pharmaceutical company, has announced it has completed enrollment for a pivotal Phase 2 clinical trial for Clearazide for the treatment of early-stage cutaneous T-cell lymphoma (CTCL - stages 1-2a). The study, which is being conducted under a Special Protocol Assessment (SPA) with the FDA, has enrolled 260 patients in 13 of the top cancer centers in the US. Yaupon expects the last patient to complete treatment in the study by June of 2010 and, assuming positive results, will file its NDA shortly thereafter.

Genetic Immunity, InPlay: Company To Present At Phacilitate's 8th Annual European Vaccine Forum
Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary"s premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on an ongoing basis.
News of the day
Care Management Reduces Depression And Suicidal Thoughts In Older Primary Care Patients
Depression in older adults too often goes unrecognized and untreated, resulting in untold misery, worsening of medical illness, and early death. A new study has identified one important remedy: Adding a trained depression care manager to primary care practices can increase the number of patients receiving treatment, lead to a higher remission rate of depression, and reduce suicidal thoughts.
Endocrinology

OneTouch(R) Ping™ Glucose Management System Approved By Health Canada

Animas Corporation announcedthe approval of its OneTouch® Ping™ Glucose Management System by Health Canada. OneTouch Ping is the first full-feature insulin pump that wirelessly communicates with a blood glucose meter-remote. Using the OneTouch Ping meter-remote, a person can calculate insulin doses and opt to wirelessly instruct the pump to deliver them without touching the pump at all, giving patients more freedom and flexibility in using their insulin pump. "OneTouch Ping provides patients with unique capabilities designed to make life with diabetes easier and more discreet. A combination of the advanced insulin pump technology from Animas and trusted OneTouch blood glucose monitor technology, the OneTouch Ping frees people living with diabetes from multiple daily injections, while offering discretion and convenience through remote insulin dosing," said Henry Anhalt, D.O., Director of Medical Affairs, Animas Corporation. "Animas is pleased to bring this advancement to people with diabetes in Canada." OneTouch Ping also marks the first integrated product from two companies within the diabetes care group of Johnson & Johnson: Animas makers of insulin pumps and LifeScan makers of the OneTouch brand of glucose meters and OneTouch® Ultra® Test Strips. OneTouch Ping also offers the following: - Lifestyle-focused pump performance - the pump can be clipped to a belt, tucked in a pocket, or secured under clothing, is waterproof up to 3.6 meters (12 feet) for 24 hours, and has a color screen for outstanding pump readability - Individualized control - delivers lowest basal increments (0.025 U/hr) and lowest bolus increments (0.05 U) available to more precisely match patient insulin needs - Proven blood glucose monitoring technology - the meter-remote utilizes the OneTouch® Ultra® test strip, the #1-selling test strip in Canada and #1 test strip preferred among insulin users in Canada. OneTouch® Ultra® test strips have more than 6 years of proven accuracy and use patented DoubleSure™ technology to automatically check and confirm results for accuracy ezManager® MAX Diabetes Management Software The OneTouch Ping system will also work with the ezManager® MAX Diabetes Management Software designed to allow users to download important diabetes management data from the insulin pump and meter-remote. Integrated blood glucose data from the meter-remote and insulin dosing data may be downloaded for review, analysis and evaluation of insulin delivery and blood glucose history to better inform healthcare decision-making. The ezManager® MAX software is MAC and PC compatible. OneTouch Ping will be available for shipment on Friday, July 24. Customers can order at any time by calling 1-866-406-4844 or by visiting http://www.OneTouchPing.ca. Animas Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009